Cancer-associated_cachexia

Corrigendum to "Identifying cancer cachexia in patients without weight loss information: machine learning approaches to address a real-world challenge" Am J Clin Nutr 116 (2022) 1229-1239.

๐Ÿ—“๏ธ 2025-02-12
๐Ÿ“ฐ Publication: American Journal Of Clinical Nutrition
Read MoreCorrigendum to "Identifying cancer cachexia in patients without weight loss information: machine learning approaches to address a real-world challenge" Am J Clin Nutr 116 (2022) 1229-1239.

Diagnostic Criteria for Cancer-Associated Cachexia: Insights from a Multicentre Cohort Study.

To explore the association between cachexia, as defined by different diagnostic criteria, and the risk of mortality in individuals with cancer. We also examined which diagnostic criteria are more feasible and appropriate for cancer-associated cachexia in clinical practice. A multicentre...

๐Ÿ—“๏ธ 2025-02-01
๐Ÿ“ฐ Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreDiagnostic Criteria for Cancer-Associated Cachexia: Insights from a Multicentre Cohort Study.

Early identification of potentially reversible cancer cachexia using explainable machine learning driven by body weight dynamics: a multicenter cohort study.

Cachexia is associated with multiple adverse outcomes in cancer. However, clinical decision-making for oncology patients at the cachexia stage presents significant challenges. This study aims to develop a machine learning (ML) model to identify potentially reversible cancer cachexia (PRCC). This...

๐Ÿ—“๏ธ 2025-01-08
๐Ÿ“ฐ Publication: American Journal Of Clinical Nutrition
Read MoreEarly identification of potentially reversible cancer cachexia using explainable machine learning driven by body weight dynamics: a multicenter cohort study.

Selpercatinib mitigates cancer cachexia independent of anti-tumor activity in the HT1080 tumor model.

Anorexia is a major cause of cancer cachexia and is induced by growth differentiation factor-15 (GDF15), which activates the rearranged during transfection (RET) protein tyrosine kinase in the hindbrain through GDF family receptor ฮฑ-like (GFRAL), raising the possibility of targeting...

๐Ÿ—“๏ธ 2025-01-06
๐Ÿ“ฐ Publication: Cancer Letters
Read MoreSelpercatinib mitigates cancer cachexia independent of anti-tumor activity in the HT1080 tumor model.

Brown adipose tissue is associated with reduced weight loss and risk of cancer cachexia: A retrospective cohort study.

Brown adipose tissue (BAT) has been mainly investigated as a potential target against cardiometabolic disease, but it has also been linked to cancer-related outcomes. Although preclinical data support that BAT and the thermogenic adipocytes in white adipose tissue may play...

๐Ÿ—“๏ธ 2024-12-30
๐Ÿ“ฐ Publication: Clinical Nutrition
Read MoreBrown adipose tissue is associated with reduced weight loss and risk of cancer cachexia: A retrospective cohort study.

Local Inflammation Precedes Diaphragm Wasting and Fibrotic Remodelling in a Mouse Model of Pancreatic Cancer.

Cancer cachexia represents a debilitating muscle wasting condition that is highly prevalent in gastrointestinal cancers, including pancreatic ductal adenocarcinoma (PDAC). Cachexia is estimated to contribute to ~30% of cancer-related deaths, with deterioration of respiratory muscles suspected to be a key...

๐Ÿ—“๏ธ 2025-02-01
๐Ÿ“ฐ Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreLocal Inflammation Precedes Diaphragm Wasting and Fibrotic Remodelling in a Mouse Model of Pancreatic Cancer.

Novel oral compound Z526 mitigates cancer-associated cachexia via intervening NF-ฮบB signaling and oxidative stress.

Cancer-associated cachexia (CAC) is a severe metabolic disorder syndrome mainly characterized by muscle and fat loss, which accounts for one-third of cancer-related deaths. No effective therapeutic approach that could fully reverse CAC is available. NF-ฮบB signaling and oxidative stress play...

๐Ÿ—“๏ธ 2024-04-08
๐Ÿ“ฐ Publication: Genes & Diseases
Read MoreNovel oral compound Z526 mitigates cancer-associated cachexia via intervening NF-ฮบB signaling and oxidative stress.

Systemic metabolic crosstalk as driver of cancer cachexia.

Cachexia is a complex metabolic disorder characterized by negative energy balance due to increased consumption and lowered intake, leading to progressive tissue wasting and inefficient energy distribution. Once considered as passive bystander, metabolism is now acknowledged as a regulator of...

๐Ÿ—“๏ธ 2025-01-04
๐Ÿ“ฐ Publication: Trends In Endocrinology And Metabolism
Read MoreSystemic metabolic crosstalk as driver of cancer cachexia.

The microbiota-derived bile acid taurodeoxycholic acid improves hepatic cholesterol levels in mice with cancer cachexia.

Alterations in bile acid profile and pathways contribute to hepatic inflammation in cancer cachexia, a syndrome worsening the prognosis of cancer patients. As the gut microbiota impinges on host metabolism through bile acids, the current study aimed to explore the...

๐Ÿ—“๏ธ 2025-01-08
๐Ÿ“ฐ Publication: Gut Microbes
Read MoreThe microbiota-derived bile acid taurodeoxycholic acid improves hepatic cholesterol levels in mice with cancer cachexia.

Disrupted methionine cycle triggers muscle atrophy in cancer cachexia through epigenetic regulation of REDD1.

The essential amino acid methionine plays a pivotal role in one-carbon metabolism, facilitating the production of S-adenosylmethionine (SAM), a critical supplier for DNA methylation and thereby a modulator of gene expression. Here, we report that the methionine cycle is disrupted...

๐Ÿ—“๏ธ 2024-12-20
๐Ÿ“ฐ Publication: Cell Metabolism
Read MoreDisrupted methionine cycle triggers muscle atrophy in cancer cachexia through epigenetic regulation of REDD1.

Clinical impact of cancer cachexia on the outcome of patients with non-small cell lung cancer with PD-L1 tumor proportion scores of โ‰ฅ50% receiving pembrolizumab monotherapy versus immune checkpoint inhibitor with chemotherapy.

This retrospective, multicenter cohort study aimed to determine whether cancer cachexia serves as a biomarker for determining the most effective treatment for patients having non-small-cell lung cancer (NSCLC) with high programmed death ligand 1 (PD-L1) expression treated with immune checkpoint...

๐Ÿ—“๏ธ 2024-12-16
Read MoreClinical impact of cancer cachexia on the outcome of patients with non-small cell lung cancer with PD-L1 tumor proportion scores of โ‰ฅ50% receiving pembrolizumab monotherapy versus immune checkpoint inhibitor with chemotherapy.

Impact of Cachexia and First-Line Systemic Therapy for Previously Untreated Advanced Non-Small Cell Lung Cancer: NEJ050A.

Cancer cachexia complicates advanced non-small cell lung cancer (NSCLC); however, it remains unclear how often cachexia occurs and how it affects the course of chemotherapy in patients receiving first-line systemic therapy. We conducted a multicentre, prospective observational study and enrolled...

๐Ÿ—“๏ธ 2024-10-01
๐Ÿ“ฐ Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreImpact of Cachexia and First-Line Systemic Therapy for Previously Untreated Advanced Non-Small Cell Lung Cancer: NEJ050A.

Subscribe to the SCWD Newsletter

Stay Informed with the Latest Updates and Exclusive Insights!